Pharma Journalist -

Patients with HER2-positive breast cancer face something of a predicament: The most effective drug to treat the cancer is also the most toxic. Trastuzumab, sold under the brand name…
Read More...

Roche announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition…
Read More...

Roche announced that the European Commission has approved Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII…
Read More...

CARB-X announced that it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early…
Read More...

Pharmaceutics International announced that the U.S. Food and Drug Administration (FDA) has issued their Establishment Inspection Reports (EIRs) for both FEI registration numbers…
Read More...

BioArctic AB (publ) announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in…
Read More...

Seres Therapeutics announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting…
Read More...

R&D alliance will enable ‘promising innovations to advance beyond their laboratory roots’ Harvard University and Deerfield Management, a health care investment firm, have…
Read More...

Hoth Therapeutics, a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as…
Read More...

Esperion announced that results from the 2,230 patient, 52-week, Phase 3 long-term safety study of bempedoic acid (CLEAR Harmony, also known as Study 1 or 1002-040) were published today…
Read More...